LT3470077T - Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas - Google Patents

Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas

Info

Publication number
LT3470077T
LT3470077T LTEP18201960.4T LT18201960T LT3470077T LT 3470077 T LT3470077 T LT 3470077T LT 18201960 T LT18201960 T LT 18201960T LT 3470077 T LT3470077 T LT 3470077T
Authority
LT
Lithuania
Prior art keywords
diseases
pharmacological chaperone
predict response
chaperone treatment
treatment
Prior art date
Application number
LTEP18201960.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Elfrida Benjamin
Hung V Do
Xiaoyang Wu
John Flanagan
Brandon Wustman
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40957500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3470077(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT3470077T publication Critical patent/LT3470077T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
LTEP18201960.4T 2008-02-12 2009-02-12 Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas LT3470077T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2814108P 2008-02-12 2008-02-12
US3568408P 2008-03-11 2008-03-11
US9363108P 2008-09-02 2008-09-02
US11349608P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
LT3470077T true LT3470077T (lt) 2021-02-25

Family

ID=40957500

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18201960.4T LT3470077T (lt) 2008-02-12 2009-02-12 Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
LTEP15162630.6T LT2946785T (lt) 2008-02-12 2009-02-12 Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15162630.6T LT2946785T (lt) 2008-02-12 2009-02-12 Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas

Country Status (16)

Country Link
US (8) US8592362B2 (2)
EP (4) EP2946785B1 (2)
JP (7) JP5844045B2 (2)
AU (7) AU2009214648B2 (2)
CA (1) CA2715407C (2)
CY (3) CY1116466T1 (2)
DK (3) DK2946785T3 (2)
ES (3) ES2716502T3 (2)
HR (3) HRP20150728T1 (2)
HU (3) HUE051377T2 (2)
LT (2) LT3470077T (2)
MX (1) MX2010008835A (2)
PL (3) PL2946785T3 (2)
PT (3) PT3470077T (2)
SI (3) SI3470077T1 (2)
WO (1) WO2009102895A2 (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
US20110136151A1 (en) * 2008-03-12 2011-06-09 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for pompe disease
US20110112041A1 (en) * 2009-10-01 2011-05-12 Baylor Research Institute Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10172924B2 (en) 2015-03-19 2019-01-08 Translate Bio, Inc. MRNA therapy for pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
PT4285902T (pt) 2015-12-30 2026-02-10 Amicus Therapeutics Inc Alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102004114B1 (ko) * 2016-03-22 2019-07-26 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
CN109475607B (zh) 2016-03-30 2022-04-26 阿米库斯治疗学公司 包含重组酸性α-葡糖苷酶的配制品
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
AR109103A1 (es) 2016-07-19 2018-10-31 Amicus Therapeutics Inc Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
JP6546135B2 (ja) 2016-08-24 2019-07-17 株式会社ノリタケカンパニーリミテド 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット
CA3039673A1 (en) * 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
PT4324522T (pt) 2017-05-30 2026-03-13 Amicus Therapeutics Inc Métodos de tratamento de pacientes com fabry tendo insuficiência renal
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
SMT202400027T1 (it) 2018-02-06 2024-03-13 Amicus Therapeutics Inc Trattamento di pazienti con malattia di fabry classica con migalastat
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
AR120055A1 (es) 2019-06-11 2022-02-02 Amicus Therapeutics Inc Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
EP3851105B1 (en) * 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
JP2022546587A (ja) 2019-09-06 2022-11-04 アミカス セラピューティックス インコーポレイテッド 生物製剤の捕捉及び精製のための方法
EP4114390B1 (en) * 2020-03-06 2024-12-04 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
EP4370120A1 (en) 2021-07-12 2024-05-22 Amicus Therapeutics, Inc. Methods of treating fabry disease in pediatric patients
JP2025515159A (ja) 2022-05-05 2025-05-13 アミカス セラピューティックス インコーポレイテッド ポンペ病の治療方法
EP4626465A1 (en) 2022-12-02 2025-10-08 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients
JP2025540135A (ja) 2022-12-02 2025-12-11 アミカス セラピューティックス インコーポレイテッド 小児患者の乳児発症型ポンペ病の治療方法
US20240197706A1 (en) 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat
WO2026006625A1 (en) 2024-06-26 2026-01-02 Amicus Therapeutics, Inc. Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21381A (en) * 1858-08-31 Bracelet
US270486A (en) * 1883-01-09 Bundle-separating attachment for self-binding harvesters
US203019A (en) * 1878-04-30 Improvement in circuits for acoustic or telephonic telegraphs
US264467A (en) * 1882-09-19 Chables h
US3586908A (en) 1969-02-28 1971-06-22 Robert E Vosteen Automatic potential control system for electrophotography apparatus
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
CA2250780A1 (en) 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
EP2932982B1 (en) * 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101541172A (zh) * 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
PL2027137T3 (pl) 2005-06-08 2015-08-31 Amicus Therapeutics Inc Oczyszczanie imino- i aminocukrów
US7790364B2 (en) * 2006-01-27 2010-09-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
JP5739898B2 (ja) 2009-11-17 2015-06-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３）
CN103974619B (zh) 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
HK1209625A1 (en) 2012-07-17 2016-04-08 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
KR102004114B1 (ko) 2016-03-22 2019-07-26 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
AR109103A1 (es) 2016-07-19 2018-10-31 Amicus Therapeutics Inc Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
SMT202400027T1 (it) 2018-02-06 2024-03-13 Amicus Therapeutics Inc Trattamento di pazienti con malattia di fabry classica con migalastat
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
AR120055A1 (es) 2019-06-11 2022-02-02 Amicus Therapeutics Inc Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene

Also Published As

Publication number Publication date
CA2715407A1 (en) 2009-08-20
EP2946785A1 (en) 2015-11-25
US9095584B2 (en) 2015-08-04
US20250082621A9 (en) 2025-03-13
JP2011514152A (ja) 2011-05-06
HRP20201827T1 (hr) 2021-01-08
JP2015091239A (ja) 2015-05-14
CA2715407C (en) 2022-07-26
LT2946785T (lt) 2019-02-11
US10813921B2 (en) 2020-10-27
JP5844045B2 (ja) 2016-01-13
EP2946785B1 (en) 2018-10-24
EP2252313A4 (en) 2011-04-13
SI2252313T1 (sl) 2015-08-31
HRP20150728T1 (hr) 2015-08-14
JP6672013B2 (ja) 2020-03-25
PL3470077T3 (pl) 2021-04-06
AU2016206297A1 (en) 2016-08-04
JP2025148351A (ja) 2025-10-07
USRE48608E1 (en) 2021-06-29
US20190000818A1 (en) 2019-01-03
WO2009102895A2 (en) 2009-08-20
US20170003301A1 (en) 2017-01-05
US20110212996A1 (en) 2011-09-01
AU2017268649A1 (en) 2018-01-04
AU2014221321B2 (en) 2016-05-12
EP3470077A1 (en) 2019-04-17
HUE026543T2 (hu) 2016-06-28
SI3470077T1 (sl) 2020-12-31
HRP20190143T1 (hr) 2019-03-22
US20210251971A1 (en) 2021-08-19
US20150342940A1 (en) 2015-12-03
AU2019219727A1 (en) 2019-09-12
US20110152319A1 (en) 2011-06-23
DK2946785T3 (en) 2019-02-18
CY1121386T1 (el) 2020-05-29
PL2252313T3 (pl) 2015-09-30
PT2252313E (pt) 2015-08-26
AU2021218172A1 (en) 2021-10-07
AU2009214648B2 (en) 2014-11-13
JP2016163571A (ja) 2016-09-08
AU2024219997A1 (en) 2024-10-10
JP6837469B2 (ja) 2021-03-03
DK2252313T3 (en) 2015-07-13
ES2836121T3 (es) 2021-06-24
HUE042882T2 (hu) 2019-07-29
PT3470077T (pt) 2020-11-30
AU2009214648A1 (en) 2009-08-20
MX2010008835A (es) 2010-10-20
AU2019219727B2 (en) 2021-05-20
PT2946785T (pt) 2019-02-01
CY1123816T1 (el) 2022-03-24
JP2021097673A (ja) 2021-07-01
EP2252313B1 (en) 2015-04-08
ES2541933T3 (es) 2015-07-28
JP2023109807A (ja) 2023-08-08
DK3470077T3 (da) 2020-11-30
ES2716502T3 (es) 2019-06-12
EP2252313A2 (en) 2010-11-24
SI2946785T1 (sl) 2019-02-28
PL2946785T3 (pl) 2019-04-30
US20140206721A1 (en) 2014-07-24
WO2009102895A3 (en) 2009-12-23
EP3824900A1 (en) 2021-05-26
AU2014221321A1 (en) 2014-10-02
CY1116466T1 (el) 2017-03-15
EP3470077B1 (en) 2020-08-26
US9545397B2 (en) 2017-01-17
JP7277493B2 (ja) 2023-05-19
JP2019088289A (ja) 2019-06-13
HUE051377T2 (hu) 2021-03-01
US8592362B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
HRP20190143T1 (hr) Postupak za predviđanje odgovora na liječenje bolesti farmakološkim šaperonom
IL219051A0 (en) Methods to predict clinical outcome of cancer
IL209855A0 (en) Supression of neuroedocrine diseases
EP2496176A4 (en) ENTZELLULARISIERUNGSVERFAHREN
PT2435825E (pt) Métodos para o tratamento de doenças
IL216951A0 (en) Method for treatment of diseases
EP2517095A4 (en) ABOUT STORAGE HANDLING
EP2464376A4 (en) METHOD FOR REPAIRING NERVE DENDING
PL2504698T3 (pl) Sposób przewidywania odpowiedzi choroby nowotworowej na środek terapeutyczny
FR2945911B1 (fr) Procede de traitement contre l'ambroisie